Forensic Science

Community information
Join the BrightTALK forensic science community for access to online forensics training from respected professionals in the field. Study forensic science online to learn necessary skills for trace evidence in forensics, liquid and gas chromatography and sample preparation. You can also attend live webinars to interact with forensic scientists and have your questions answered.
  • Biological terror agents are frequently spore-forming bacteria and hardy in the environment, intended to persist despite best efforts at disinfection. This webinar explores the field of UV-C disinfection and the power of pulsed-xenon UV disinfection systems to neutralize such threats. Full spectrum pulsed-xenon UV is lab-tested to deactivate bioterrorism agents in the environment, expanding the options for protecting first responders and armed forces from dangerous pathogens.
  • COPD is a widespread, costly and largely preventable condition which affects over 300 million people worldwide and is recognised as the ‘third-leading’ cause of death in most countries. Adherence rates among patients with the condition are seen to be low, despite evidence that shows appropriate use of medication and sensible lifestyle changes can reduce mortality by 60% and hospital admissions by as much as 42%.

    Given the proven increase in quality of life when adherence occurs, and yet the persistence of non-adherence globally, there is clearly a disconnect. So why is poor self-management so prevalent and what can we do about it?

    In conjunction with self-management and behavioural change specialists Atlantis Healthcare, we present a multi-stakeholder webinar and debate, which will combine real world patient needs with expertise from healthcare, pharma and patient advocates to look at the challenges to successful self-management/adherence and ascertain what the industry can do to better support patients in achieving optimum outcomes.

    The webinar is comprised of 15 minutes of presentation and 40 minutes of live debate - which you can participate in, sending questions to the panel.

    A live tweetchat (#rwCOPD) will follow the webinar, enabling full interaction across all stakeholders to further delve into this topic and explore some of the issues and solutions raised during the webcast.

    This is the second webinar within the Patient Insights Summarized series.

    Your panel for this event is:

    Ana-maria Arboleda, Managing Director, Atlantis Healthcare Spain
    Dr Joan Escarrabill, Director of the Master Plan for Respiratory Diseases, Ministry of Health (Catalonia)
    Prof. John Weinman, Head of Health Psychology, Atlantis Healthcare
    Rolf Taylor, ‎Senior Director, Corporate Development, COPD Foundation
    Paul Tunnah (Moderator), CEO, pharmaphorum
  • This session gives an overview of the support available from the NIHR Clinical Research Network life-sciences industry team at a local and National level and explains how the network works in partnership with you to ensure your study is set up rapidly and recruits to time and target.

    Guidance on communication routes and our query resolution pathway is included.

    The webinar will also look at up to date performance data, how we collect it and how this information is transformed to ensure studies and sites are actively managed to deliver.

    Who should view this session?

    "Getting the best from the Network" is a must see for any CRA, Start up manager, study manager or NHS R&D manager who is involved in setting up and managing commercial contract clinical research in the NHS.
  • The truth about delivering clinical research in the UK

    - Are you looking to deliver your research within Europe?
    - Need multiple, reliable sites?
    - Do you want to know why you should come to the UK?

    In the past the UK’s reputation for delivering clinical research was questionable. But that’s all changed. Over the last six years the research landscape here has changed dramatically allowing us to make great strides in delivering research for the life-sciences industry. So whether you’re a small CRO, a medium med tech, or a pharma giant - we can help you.

    The National Institute for Health Research (NIHR) Clinical Research Network* (see below) is hosting a live webinar which will explode common myths around the UK’s ability to deliver commercial clinical research. This session will be hosted by Matt Cooper, Life-sciences Development Director. It will include performance data that will demonstrate why the UK should be your first choice for clinical research. You can find out:

    - How much the UK’s market volume of commercial contract research (supported by the NIHR CRN) has changed
    - What percentage of the UK’s National Health Service (NHS) is actively delivering commercial contract research studies (with support from the NIHR CRN)
    - On average how many days it takes for NHS sites to get regulatory approval for research to take place (with NIHR CRN support)
    - What percentage of commercial contract studies (supported by the NIHR CRN) are delivered to time and target
    - How we are keeping clinical research in the public eye
    - How the UK is sharpening its competitive edge by achieving more and more key first global patient milestones
  • With the advent of NGS and existing molecular approaches, why is IHC unique and relevant for companion diagnostics? January 22, 2015 to learn more from Dr. Mary Padilla, Pathologist, Senior Medical Director, Companion Diagnostics, Ventana Medical Systems Inc. If you provide companion diagnostic services, develop targeted therapies, or prescribe targeted therapies, then this is the webinar for you!
  • With challenges to highly priced rare disease medicines and the Cancer Drug Fund evolving again – what is next, what are the ramifications for high priced/innovative treatments delivering beneficial outcomes to defined patient populations in the UK and how can pharma navigate seemingly choppy waters of access for rare disease treatments and orphan drugs?

    Working in partnership with IMS Health, pharmaphorum has assembled an expert panel including NHS England’s Malcolm Qualie, Alan Kane of Shire Pharmaceuticals, Angela McFarlane of IMS Health, the Cystic Fibrosis Trust's Nick Medhurst and pharmaphorum’s own Paul Tunnah to present and debate around these issues in a free to attend one hour webinar.

    This event will cover:
    • Access, in the UK, to higher priced drugs/innovative treatments
    • Rare Disease/Orphan Drug access in the UK
    • The evolution of the Cancer Drugs Fund - what does this look like, what could it mean for pharma/healthcare

    It will also enable frank discussion around the new NHS England processes.
  • Continuing concerns exist in the clinical laboratory community about the appropriate methodologies for satisfying requirements for calibration verification and linearity testing.

    During his presentation, Dr. Jack Zakowski will discuss issues associated with these regulatory requirements and will outline approaches to satisfy them.
  • Key Topics:

    *Insight:
    What is your multichannel maturity vs industry average and vs best-practices in leading industries?

    *Innovation:
    What’s your 3-year strategy for the customer-centric New Normal?

    *Integrated execution:
    How do you set up an agile internal network to deliver a consistently great customer experience?

    *Impact:
    How do you assess whether you are moving in the right direction?
  • In this presentation we will re-visit an often overlooked parameter in the CBC, the MPV. This parameter has critical clinical applications, such as discriminating between thrombocytopenias caused by bone marrow disease (low platelet production) versus those caused by increased platelet destruction in the circulation.
  • - Are you working for a Contract Research Organisation (CRO)?
    - Are you looking to place your research within the UK?
    - Do you want to know how the CRN can help deliver your study?

    In the past the UK’s reputation for delivering clinical research was questionable. But that’s all changed. Over the last six years the research landscape here has changed dramatically allowing us to make great strides in delivering commercial contract research.

    The National Institute for Health Research (NIHR) Clinical Research Network is hosting a live webinar which will explain how we work together with CROs to meet the needs of the life-sciences industry. Not only will we explode common myths around the UK’s ability to deliver commercial contract research, we will also use performance data to demonstrate why the UK should be your first choice for clinical research delivery.

    This session will be hosted by Dr Matt Cooper, Life-sciences Development Director, of the NIHR Clinical Research Network. It will include:

    - An explanation of how CROs fit into the UK’s research delivery infrastructure
    - A look at the UK’s market volume of commercial contract research
    - The percentage of the UK’s National Health Service (NHS) that is actively delivering commercial contract research studies with our support
    - Downward trends in time taken for NHS sites to get regulatory approval for research to take place
    - The proportion of commercial contract studies that we are delivering to time and target
    - How we are keeping clinical research in the public eye
    - Information on data tools that are helping to UK to gain ground in research delivery
    - How the UK is sharpening its competitive edge by achieving more and more key first global patient milestones
  • Non-adherence to self-management regimens in diabetes is globally a widespread, costly and ultimately life threatening issue.

    Reasons for non-adherence are complex as the nature of the condition involves adherence to lifestyle, medication and diet changes, which individuals at times can find difficult to accept and adjust to. It is important to consider that the factors that influence each individual's ability to self manage are often very different and can equally affect patient outcomes, making this a globally recognised problem.

    Working in collaboration with self-management and health psychology experts, Atlantis Healthcare, this pharmaphorum webinar will combine direct insights from leading patient advocates (and diabetes patients themselves) Kerri Sparling (type 1 diabetes patient and Editor of Six Until Me) and Simon O’Neill (type 2 diabetes patient and Director of Health Intelligence and Professional Liaison, Diabetes UK).


    The 15 minute presentation and 40 minute panel discussion will consider patient insights from our recent 'managing diabetes in the real world' tweetchat. With additional expertise provided by Atlantis Healthcare's Dr Sinead Ni Mhurchadha (Health Psychology Specialist) and Charles Mackinnon (Director of NHS Partnerships and non-Executive Director to Manchester AHSN ) to give a real world view on the unique solutions needed to effectively manage adherence and support self-management .


    The webinar will also look at how healthcare stakeholders (pharma, payers and healthcare professionals) can support Type 1 and Type 2 to manage their condition, understand better the challenges these patients face and how we can help support improved outcomes for diabetes patients worldwide.

    The webinar takes place on October 29th at 3pm (UK) / 4pm (Europe) / 11am Eastern US.
  • Key topics:

    -Which channel metrics are key
    -How to analyze and visualize complex channel data
    -How to operationalize these data
  • Our sixth and final webinar in this series will be an interactive evaluation and troubleshooting of customer assays. Please send us your questions and/or failed assays and we will go through troubleshooting together to identify the problem. We will need information on the target sequence, primers and probes, how the assay was designed and QC for the primers and probes, amplification plots and melting curves (if SYBR Green/Molecular Beacon or Scorpion assay).
  • A pharmaceutical industry multi-stakeholder interactive discussion on some of the unique challenges faced today in marketing pharma brands effectively to exploit areas of unrealised opportunity, plus what is required from both strategic marketing and research to deliver in view of this.
  • Our sixth and final webinar in this series will be an interactive evaluation and troubleshooting of customer assays. Please send us your questions and/or failed assays and we will go through troubleshooting together to identify the problem. We will need information on the target sequence, primers and probes, how the assay was designed and QC for the primers and probes, amplification plots and melting curves (if SYBR Green/Molecular Beacon or Scorpion assay).
  • Statistical data analysis is commonly applied to three different types of qPCR data: absolute quantification, relative quantification and expression profiling. Characterization of variability in the data is important both as an estimate of the data reliability as well as an estimate of the tolerance levels of scientific conclusions. Researchers go through a series of methods to minimize technical variability to arrive at scientific results with high precision, while at the same time maximizing the natural biological variability with the aim to characterize that as fully as possible. This presentation illustrates how reagent and sample quality as well as correct application of methods help researchers and technicians arrive at high quality scientific results and conclusions.
  • Statistical data analysis is commonly applied to three different types of qPCR data: absolute quantification, relative quantification and expression profiling. Characterization of variability in the data is important both as an estimate of the data reliability as well as an estimate of the tolerance levels of scientific conclusions. Researchers go through a series of methods to minimize technical variability to arrive at scientific results with high precision, while at the same time maximizing the natural biological variability with the aim to characterize that as fully as possible. This presentation illustrates how reagent and sample quality as well as correct application of methods help researchers and technicians arrive at high quality scientific results and conclusions.
  • Optimization and validation of the assay is absolutely essential even if the researcher is using a pre-designed, commercially available assay. There are number of factors, like primer and probe concentration or Tm gradient, which could be optimized in order to get a sensitive, efficient and reproducible assay.
  • Optimization and validation of the assay is absolutely essential even if the researcher is using a pre-designed, commercially available assay. There are number of factors, like primer and probe concentration or Tm gradient, which could be optimized in order to get a sensitive, efficient and reproducible assay.
  • To obtain reliable data from PCR, it is essential to have a good quality sample. The consistent analysis of quantity and quality of the sample can help to eliminate possible contamination and prevent from inhibition of the assay and false negative or positive results.
  • To obtain reliable data from PCR, it is essential to have a good quality sample. The consistent analysis of quantity and quality of the sample can help to eliminate possible contamination and prevent from inhibition of the assay and false negative or positive results.
  • As a representative two-dimensional (2D) nanomaterial, graphene has attracted significant attention in the field of ultrasensitive sensors because of its excellent electronic and chemical properties, and large specific surface area. In this talk, three different types of graphene-based materials with unique features, i.e., reduced graphene oxide (rGO), crumpled graphene (CG), and vertically-oriented graphene (VG), will be introduced, together with their applications for versatile biosensors based on two major biosensing mechanisms (electronic sensing and electrochemical sensing). In an electronic biosensor, graphene-based materials are functionalized with gold nanoparticle (NP)-antibody conjugates and used as a conducting channel in a field-effect transistor (FET). Electrical detection of protein binding is accomplished through FET and direct current (dc) measurements. In an electrochemical biosensor, highly electrocatalytic metal oxides are combined with graphene-based materials to offer both a high electrocatalytic activity and a high electrical conductivity for enzymeless biosensing. Biomolecules are then detected through electrochemical measurements such as cyclic voltammetry. The above-mentioned graphene-based platforms will be demonstrated for the detection of Escherichia coli (E. coli) bacteria, glucose, and various proteins.
  • Key topics:

    •How to engage the fieldforce for the multichannel future?
    •Which multichannel offerings should the fieldforce embrace?
    •How the internal organization should transform to allow for true MC reps?
    •How to train and coach them?
    •How should they be measured and compensated?
  • • Are you looking to deliver your research within Europe?
    • Need multiple, reliable sites?
    • Do you want to know why you should come to the UK?

    In the past the UK’s reputation for delivering clinical research was questionable. But that’s all changed. Over the last six years the research landscape here has changed dramatically allowing us to make great strides in delivering research for the life-sciences industry. So whether you’re a small CRO, a medium med tech, or a pharma giant - we can help you.

    The NIHR Clinical Research Network is hosting a live webinar which will explode common myths around the UK’s ability to deliver commercial clinical research. This session will be hosted by Matt Cooper, Life-sciences Development Director, of the National Institute for Health Research Clinical Research Network (NIHR CRN). It will include performance data that will demonstrate why the UK should be your first choice for clinical research. You can find out:

    • How much the UK’s market volume of commercial contract research (supported by the NIHR CRN) has changed
    • What percentage of the UK’s National Health Service (NHS) is actively delivering commercial contract research studies (with support from the NIHR CRN)
    • On average how many days it takes for NHS sites to get regulatory approval for research to take place (with NIHR CRN support)
    • What percentage of commercial contract studies (supported by the NIHR CRN) are delivered to time and target
    • How we are keeping clinical research in the public eye
    • How the UK is sharpening its competitive edge by achieving more and more key first global patient milestones